Tamoxifen Pharmacogenetics in Asian Breast Cancer Women

Observational Study: Biomarker Research for Tamoxifen Pharmacogenetics Among Asian Breast Cancer Patients

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01181518

Acronym

Tamoxifen

Enrollment

1000

Registered

2010-08-13

Start date

2010-08-31

Completion date

2015-12-31

Last updated

2013-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Poisoning by, Adverse Effect of and Underdosing of Tamoxifen

Keywords

Tamoxifen, Pharmacogenomics, Breast cancer

Brief summary

The clinical outcome of tamoxifen treatment in breast cancer patients may be influenced by the activity of cytochrome P450 enzymes involving in tamoxifen biotransformation.

Detailed description

The investigators investigated the prognostic and/or predictive value of genetic polymorphisms of enzymes involved in tamoxifen metabolism for the treatment outcome among Asian breast cancer patients.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* incident breast cancer patients who underwent surgery

Exclusion criteria

* previous cancer history before breast cancer diagnosis

Design outcomes

Primary

Measure	Time frame	Description
Association between genetic polymorphisms of CYP2D6, CYP2C19, and CYP3A5 and disease free survival among tamoxifen treated breast cancer patients	five years	Association between genetic polymorphisms of CYP2D6, CYP2C19, and CYP3A5 and disease free survival among tamoxifen treated breast cancer patients

Countries

South Korea

Contacts

Primary ContactJi-Yeob Choi, Ph.D.

jychoi@inje.ac.kr82-51-890-8663

Outcome results